Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rifaximin vaginal tablets for bacterial vaginosis
2009-011826-32Phase 2Completed
- Sponsor
- Alfasigma
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifaximin in bacterial vaginosis (BV) (4 arms), sponsored by Alfasigma. Primary endpoint: Primary remission endpoint. Started May 2009; status: completed.
02
Drugs
rifaximin
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on 2009-011826-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011826-32.